




# How to get your adult GERD patients started

<p><b>1</b> In your EMR, select:</p>	<p><b>2</b> Select the relevant ICD-10-CM code*:</p>	<p><b>3</b> Submit the prescription:</p>
<p><b>A</b></p>  <p>Boise, Idaho</p> <p>OR</p> <p><b>B</b></p> <p><b>Your local pharmacy</b></p> <p>Scan the QR code on the back to download the Savings Card for your eligible commercial patients</p>	<p>Three common ICD-10 codes are listed below that may be appropriate for a patient with GERD. Please refer to an ICD-10-CM resource for additional codes that may be applicable to your patient.</p> <ul style="list-style-type: none"> <li>• <b>K21.00:</b> Gastro-esophageal reflux disease with esophagitis, <b>without</b> bleeding</li> <li>• <b>K21.01:</b> Gastro-esophageal reflux disease with esophagitis, <b>with</b> bleeding</li> <li>• <b>K21.9:</b> Gastro-esophageal reflux disease <b>without</b> esophagitis</li> </ul> <p><small>*The information herein is provided for informational purposes only. Phathom cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the healthcare provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.</small></p>	<p><b>A</b></p> <p><b>Healing of Erosive GERD and relief of associated heartburn</b></p> <p>VOQUEZNA 20 mg, once daily for 8 weeks</p> <p>OR</p> <p><b>B</b></p> <p><b>Maintenance of healing of Erosive GERD and relief of associated heartburn</b></p> <p>VOQUEZNA 10 mg, once daily for up to 6 months</p> <p>OR</p> <p><b>C</b></p> <p><b>Relief of heartburn associated with Non-Erosive GERD</b></p> <p>VOQUEZNA 10 mg, once daily for 4 weeks</p>

## Flexible once-daily dosing, taken with or without food<sup>1</sup>

GERD=Gastroesophageal Reflux Disease.

### INDICATIONS AND USAGE

VOQUEZNA<sup>®</sup> (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated in adults:

- for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD.
- to maintain healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD.
- for the relief of heartburn associated with Non-Erosive GERD.

### IMPORTANT SAFETY INFORMATION

#### CONTRAINDICATIONS

VOQUEZNA is contraindicated in patients with a known hypersensitivity to vonoprazan or any component of VOQUEZNA, or in patients receiving rilpivirine-containing products.

#### WARNINGS AND PRECAUTIONS

**Presence of Gastric Malignancy:** In adults, symptomatic response to therapy with VOQUEZNA does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing in patients who have a suboptimal response or an early symptomatic relapse after completing treatment with VOQUEZNA. In older patients, also consider endoscopy.

**Acute Tubulointerstitial Nephritis:** Acute tubulointerstitial nephritis (TIN) has been reported with VOQUEZNA. If suspected, discontinue VOQUEZNA and evaluate patients with suspected acute TIN.

**Clostridioides difficile-Associated Diarrhea:** Published observational studies suggest that proton pump inhibitors (PPIs) may be associated with an increased risk of *Clostridioides difficile*-associated diarrhea (CDAD), especially in hospitalized patients. VOQUEZNA may also increase the risk of CDAD. Consider CDAD in patients with diarrhea that does not improve. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

**Bone Fracture:** Several published observational studies suggest that PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine, especially in patients receiving high dose (multiple daily doses) and long-term therapy (a year or longer).

Please see additional Important Safety Information on back and full [Prescribing Information](#).



Eligible patients with commercial insurance may pay as little as \$25\*

Visit [VOQUEZNAPRO.com](http://VOQUEZNAPRO.com) for full Terms and Conditions.

\*Per prescription.



Download Savings Cards for your eligible patients.

**BLINKRx**

Call for more information:  
1(844) 759-0782

*BlinkRx provides eligible patients with assistance accessing VOQUEZNA at the lowest out-of-pocket cost available to them*

## IMPORTANT SAFETY INFORMATION (cont'd)

### WARNINGS AND PRECAUTIONS (cont'd)

**Bone Fracture (cont'd):** Bone fracture, including osteoporosis-related fracture, has also been reported with vonoprazan. Use the shortest duration of VOQUEZNA appropriate to the condition being treated. Patients at risk for osteoporosis-related fractures should be managed according to the established treatment guidelines.

**Severe Cutaneous Adverse Reactions (SCAR):** Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with VOQUEZNA. Discontinue VOQUEZNA at the first signs or symptoms of SCAR or other signs of hypersensitivity and consider further evaluation.

**Vitamin B12 (Cobalamin) Deficiency:** Long-term use of acid-suppressing drugs can lead to malabsorption of Vitamin B12 caused by hypo- or achlorhydria. Vitamin B12 deficiency has been reported postmarketing with vonoprazan. If clinical symptoms consistent with vitamin B12 deficiency are observed in patients treated with VOQUEZNA, consider further workup.

**Hypomagnesemia and Mineral Metabolism:** Hypomagnesemia has been reported postmarketing with vonoprazan. Hypomagnesemia may lead to hypocalcemia and/or hypokalemia and may exacerbate underlying hypocalcemia in at-risk patients.

Consider monitoring magnesium levels prior to initiation of VOQUEZNA and periodically in patients expected to be on prolonged treatment, in patients taking drugs that may have increased toxicity in the presence of hypomagnesemia or drugs that may cause hypomagnesemia. Treatment of hypomagnesemia may require magnesium replacement and discontinuation of VOQUEZNA.

Consider monitoring magnesium and calcium levels prior to initiation of VOQUEZNA and periodically while on treatment in patients with a preexisting risk of hypocalcemia. Supplement with magnesium and/or calcium, as necessary. If hypocalcemia is refractory to treatment, consider discontinuing VOQUEZNA.

**Interactions with Diagnostic Investigations for Neuroendocrine Tumors:** Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acidity. The increased CgA level may cause false positive results in diagnostic investigations for neuroendocrine tumors. Temporarily discontinue VOQUEZNA treatment at least 4 weeks before assessing CgA levels and consider repeating the test if initial CgA levels are high.

**Fundic Gland Polyps:** Use of VOQUEZNA is associated with a risk of fundic gland polyps that increases with long-term use, especially beyond one year. Fundic gland polyps have been reported with vonoprazan in clinical trials and during postmarketing use with PPIs. Most patients who developed fundic gland polyps were asymptomatic and fundic gland polyps were identified incidentally on endoscopy. Use the shortest duration of VOQUEZNA appropriate to the condition being treated.

## ADVERSE REACTIONS

**Healing of Erosive GERD:** The most common adverse reactions ( $\geq 2\%$  of patients in the VOQUEZNA arm) include gastritis (3%), diarrhea (2%), abdominal distention (2%), abdominal pain (2%), and nausea (2%).

**Maintenance of Healed Erosive GERD:** The most common adverse reactions ( $\geq 3\%$  of patients in the VOQUEZNA arm) include gastritis (6%), abdominal pain (4%), dyspepsia (4%), hypertension (3%), and urinary tract infection (3%).

**Relief of Heartburn Associated with Non-Erosive GERD:** The most common adverse reactions ( $\geq 2\%$  of patients in the VOQUEZNA arm) include abdominal pain (2%), constipation (2%), diarrhea (2%), nausea (2%), and urinary tract infection (2%).

## DRUG INTERACTIONS

VOQUEZNA has the potential for clinically important drug interactions, including interactions with drugs dependent on gastric pH for absorption, drugs that are substrates for certain CYP enzymes, and some diagnostic tests. Avoid concomitant use of VOQUEZNA with atazanavir or nelfinavir. See full Prescribing Information for more details about important drug interactions. Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan.

## USE IN SPECIFIC POPULATIONS

**Pregnancy:** There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to VOQUEZNA during pregnancy. Healthcare providers are encouraged to register patients by calling 1-866-609-1612 or visiting <https://voqueznapregnancyregistry.com/>.

**Lactation:** There are no data on the effects of vonoprazan on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VOQUEZNA and any potential adverse effects on the breastfed child from VOQUEZNA or from the underlying maternal condition.

**Renal Impairment:** For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR < 30 mL/min).

**Hepatic Impairment:** For the healing of Erosive GERD, dosage reduction is recommended in patients with moderate to severe hepatic impairment (Child-Pugh Class B and C).

**You are encouraged to report suspected adverse reactions by contacting Phathom Pharmaceuticals at 1-888-775-PHAT (7428) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).**

**Please see additional Important Safety Information on front and full [Prescribing Information](#).**

**Reference: 1.** VOQUEZNA. Prescribing Information. Phathom Pharmaceuticals; 2025.